Similar articles

• Integrated, sequential, and contingent screening for Down syndrome - local needs should drive methodology.

  Wyatt P. Wyatt P. Prenat Diagn. 2007 Feb;27(2):186-7. doi: 10.1002/pd.1634. Prenat Diagn. 2007. PMID: 17266162 No abstract available.
• Maternal serum triple analyte screening in pregnancy.

  Cate S. Cate S. Am Fam Physician. 2000 Aug 15;62(4):738, 740. Am Fam Physician. 2000. PMID: 10969855 No abstract available.
• First- and second-trimester evaluation of risk for Down syndrome.

  Ball RH, Caughey AB, Malone FD, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Emig D, D'Alton ME; First and Second Trimester Evaluation of Risk (FASTER) Research Consortium. Ball RH, et al. Obstet Gynecol. 2007 Jul;110(1):10-7. doi: 10.1097/01.AOG.0000263470.89007.e3. Obstet Gynecol. 2007. PMID: 17601890
• Cost-effectiveness of Down syndrome screening paradigms.

  Caughey AB, Kaimal AJ, Odibo AO. Caughey AB, et al. Clin Lab Med. 2010 Sep;30(3):629-42. doi: 10.1016/j.cll.2010.04.007. Clin Lab Med. 2010. PMID: 20638577 Review.
• Antenatal screening for Down's syndrome.

  Wald NJ, Kennard A, Hackshaw A, McGuire A. Wald NJ, et al. Health Technol Assess. 1998;2(1):i-iv, 1-112. Health Technol Assess. 1998. PMID: 9561893 Review. No abstract available.